Maravai LifeSciences Holdings, Inc.

Symbol: MRVI

NASDAQ

9.86

USD

Market price today

  • -9.9573

    P/E Ratio

  • -0.0063

    PEG Ratio

  • 2.48B

    MRK Cap

  • 0.00%

    DIV Yield

Maravai LifeSciences Holdings, Inc. (MRVI) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.44%

Operating Profit Margin

-0.17%

Net Profit Margin

-0.48%

Return on Assets

-0.09%

Return on Equity

-0.28%

Return on Capital Employed

-0.03%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. William E. Martin III
Full-time employees:650
City:San Diego
Address:10770 Wateridge Circle
IPO:2020-11-20
CIK:0001823239

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.

General Outlook

When we look at how much money they make before expenses, they keep 0.438% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.167%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.478%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.091% return, is a testament to Maravai LifeSciences Holdings, Inc.'s adeptness in optimizing resource deployment. Maravai LifeSciences Holdings, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.281%. Furthermore, the proficiency of Maravai LifeSciences Holdings, Inc. in capital utilization is underscored by a remarkable -0.033% return on capital employed.

Stock Prices

Maravai LifeSciences Holdings, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $8.74, while its low point bottomed out at $8.13. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Maravai LifeSciences Holdings, Inc.'s stock market.

Liquidity Ratios

Analyzing MRVI liquidity ratios reveals its financial health of the firm. The current ratio of 1131.58% gauges short-term asset coverage for liabilities. The quick ratio (1030.61%) assesses immediate liquidity, while the cash ratio (951.66%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio1131.58%
Quick Ratio1030.61%
Cash Ratio951.66%

Profitability Ratios

MRVI profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 218.84% underscores its earnings before tax deductions. The effective tax rate stands at 126.62%, revealing its tax efficiency. The net income per EBT, -21.85%, and the EBT per EBIT, -1313.19%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -16.67%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin218.84%
Effective Tax Rate126.62%
Net Income per EBT-21.85%
EBT per EBIT-1313.19%
EBIT per Revenue-16.67%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 11.32, it details the span from stock purchase to revenue. The 10 days it takes to settle debts showcases its creditor relations. Meanwhile, a 10 cash conversion cycle and 588.22% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding1031
Days of Inventory Outstanding118
Operating Cycle180.19
Days of Payables Outstanding19
Cash Conversion Cycle161
Receivables Turnover5.88
Payables Turnover18.72
Inventory Turnover3.09
Fixed Asset Turnover1.70
Asset Turnover0.19

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.25, and free cash flow per share, -0.23, depict cash generation on a per-share basis. The cash per share value, 4.24, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.12, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.25
Free Cash Flow per Share-0.23
Cash per Share4.24
Operating Cash Flow Sales Ratio0.12
Free Cash Flow to Operating Cash Flow Ratio-0.94
Cash Flow Coverage Ratio0.06
Short Term Coverage Ratio5.35
Capital Expenditure Coverage Ratio0.52
Dividend Paid and Capex Coverage Ratio0.52

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 38.47%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.35, we discern the balance between debt and equity financing. The long-term debt to capitalization, 57.23%, and total debt to capitalization, 57.51%, ratios shed light on its capital structure. An interest coverage of -1.97 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio38.47%
Debt Equity Ratio1.35
Long Term Debt to Capitalization57.23%
Total Debt to Capitalization57.51%
Interest Coverage-1.97
Cash Flow to Debt Ratio0.06
Company Equity Multiplier3.52

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 2.19, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.90, reflects the portion of profit attributed to each share. The book value per share, 3.16, represents the net asset value distributed per share, while the tangible book value per share, 1.84, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share2.19
Net Income Per Share-0.90
Book Value Per Share3.16
Tangible Book Value Per Share1.84
Shareholders Equity Per Share3.16
Interest Debt Per Share4.38
Capex Per Share-0.50

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -67.28%, indicates top-line expansion, while the gross profit growth, -80.73%, reveals profitability trends. EBIT growth, -100.73%, and operating income growth, -100.73%, offer insights into operational profitability progression. The net income growth, -124.26%, showcases bottom-line expansion, and the EPS growth, -124.13%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-67.28%
Gross Profit Growth-80.73%
EBIT Growth-100.73%
Operating Income Growth-100.73%
Net Income Growth-124.26%
EPS Growth-124.13%
EPS Diluted Growth-146.88%
Weighted Average Shares Growth0.28%
Weighted Average Shares Diluted Growth-48.33%
Operating Cash Flow Growth-76.45%
Free Cash Flow Growth-88.31%
10-Year Revenue Growth per Share57.36%
5-Year Revenue Growth per Share57.36%
3-Year Revenue Growth per Share-25.49%
10-Year Operating CF Growth per Share45866.12%
5-Year Operating CF Growth per Share45866.12%
3-Year Operating CF Growth per Share-39.24%
10-Year Net Income Growth per Share-352.73%
5-Year Net Income Growth per Share-352.73%
3-Year Net Income Growth per Share-213.42%
10-Year Shareholders Equity Growth per Share94.63%
5-Year Shareholders Equity Growth per Share94.63%
3-Year Shareholders Equity Growth per Share244.95%
Receivables Growth-62.05%
Inventory Growth19.11%
Asset Growth-34.83%
Book Value per Share Growth-23.78%
Debt Growth4.39%
R&D Expense Growth-5.93%
SGA Expenses Growth-3.67%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 900,074,450, captures the company's total value, considering both debt and equity. Income quality, -1.06, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 36.78%, indicates the value of non-physical assets, and capex to operating cash flow, -51.93%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value900,074,450
Income Quality-1.06
Research and Development to Revenue5.98%
Intangibles to Total Assets36.78%
Capex to Operating Cash Flow-51.93%
Capex to Revenue-22.69%
Capex to Depreciation-134.38%
Stock-Based Compensation to Revenue11.97%
Graham Number8.01
Return on Tangible Assets-12.66%
Graham Net Net-0.42
Working Capital612,444,000
Tangible Asset Value242,868,000
Net Current Asset Value2,346,000
Invested Capital1
Average Receivables101,268,500
Average Payables8,360,000
Average Inventory47,274,500
Days Sales Outstanding70
Days Payables Outstanding26
Days of Inventory On Hand124
ROIC0.10%
ROE-0.29%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.18, and the price to book ratio, 3.18, reflect the market's valuation relative to the company's book value. The price to sales ratio, 9.06, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -80.94, and price to operating cash flows, 39.92, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.18
Price to Book Ratio3.18
Price to Sales Ratio9.06
Price Cash Flow Ratio39.92
Price Earnings to Growth Ratio-0.01
Enterprise Value Multiple-124.65
Price Fair Value3.18
Price to Operating Cash Flow Ratio39.92
Price to Free Cash Flows Ratio-80.94
Price to Tangible Book Ratio2.07
Enterprise Value to Sales3.12
Enterprise Value Over EBITDA20.19
EV to Operating Cash Flow7.13
Earnings Yield-13.78%
Free Cash Flow Yield7.02%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Maravai LifeSciences Holdings, Inc. (MRVI) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -9.957 in 2024.

What is the ticker symbol of Maravai LifeSciences Holdings, Inc. stock?

The ticker symbol of Maravai LifeSciences Holdings, Inc. stock is MRVI.

What is company IPO date?

IPO date of Maravai LifeSciences Holdings, Inc. is 2020-11-20.

What is company current share price?

Current share price is 9.860 USD.

What is stock market cap today?

The market cap of stock today is 2482243138.000.

What is PEG ratio in 2024?

The current -0.006 is -0.006 in 2024.

What is the number of employees in 2024?

In 2024 the company has 650.